Year: 2022

Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

Carlsbad, CA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute...

OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous...

BBS-Bioactive Bone Substitutes Plc – Insider information: BBS updates estimate of the CE marking approval schedule of ARTEBONE® Paste

BBS-Bioactive Bone Substitutes, Company announcement, Insider information, 30 December 2022 at 2:00 p.m.  BBS updates estimate of the CE marking approval schedule of ARTEBONE®...

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) – Updated Interim Results for the Six Months Ended 30 June 2022

LONDON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS...

SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)

Approximately 4,000 children in the U.S. with AKI require Continuous Kidney Replacement Therapy (CKRT) DENVER and MINNEAPOLIS , Dec. 29,...

error: Content is protected !!